Aidoc and Integral Diagnostics expand AI partnership in Australia and New Zealand

Aidoc, a global pioneer in clinical artificial intelligence (AI) solutions, has announced the expansion of its partnership with Integral Diagnostics (IDX), the leading provider of AI-driven medical imaging services, across Australia and New Zealand.

This enhanced collaboration, which started four years ago, leverages Aidoc's award-winning aiOS platform to alert radiologists and care teams to suspected and unsuspected critical findings in medical images, prioritising abnormal findings and improving the quality and timeliness of patient care across the region.

Aidoc's AI technology has firmly positioned IDX as the market leader in AI-driven medical imaging in Australia and New Zealand, with its aiOS platform automatically flagging critical pathologies, including brain aneurysms, pulmonary embolisms, stroke, and brain bleeds. 

Starting July 2025, the Australian government will fund the National Lung Cancer Screening Programme (NLCSP), a crucial step in early detection of lung cancer. IDX is currently trialling a new algorithm within Aidoc's aiOS platform designed to notify radiologists of lung nodules and measure them accurately, enabling earlier and appropriate intervention for lung cancer.

Already widely adopted across the United States and Europe, Aidoc's AI aiOS platform analyses over 3 million patients monthly and is backed by more than 150 published papers and abstracts.